Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Budesonide"" wg kryterium: Temat


Tytuł :
Combination budesonide/formoterol inhaler as sole reliever therapy in Māori and Pacific people with mild and moderate asthma.
Autorzy :
Hardy J; Senior Clinical Research Fellow, Medical Research Institute of New Zealand, Wellington.
Tewhaiti-Smith J; Clinical Research Fellow, Medical Research Institute of New Zealand, Wellington.
Baggott C; Senior Clinical Research Fellow, Medical Research Institute of New Zealand, Wellington.
Fingleton J; Consultant Physician, Capital and Coast District Health Board, Wellington.
Semprini A; Deputy Director, Medical Research Institute of New Zealand, Wellington.
Holliday M; Principal Clinical Operations, Medical Research Institute of New Zealand, Wellington.
Hancox RJ; Associate Professor, University of Otago, Dunedin.
Weatherall M; Professor of Medicine, University of Otago Wellington, Wellington.
Harwood M; Associate Professor, University of Auckland, Auckland.
Pokaż więcej
Źródło :
The New Zealand medical journal [N Z Med J] 2020 Aug 21; Vol. 133 (1520), pp. 61-72. Date of Electronic Publication: 2020 Aug 21.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-Asthmatic Agents/*therapeutic use
Asthma/*drug therapy
Budesonide, Formoterol Fumarate Drug Combination/*therapeutic use
Drug Therapy, Combination/*methods
Administration, Inhalation ; Adult ; Anti-Asthmatic Agents/administration & dosage ; Asthma/physiopathology ; Bronchodilator Agents/administration & dosage ; Bronchodilator Agents/therapeutic use ; Budesonide/administration & dosage ; Budesonide/therapeutic use ; Budesonide, Formoterol Fumarate Drug Combination/administration & dosage ; Case-Control Studies ; Disease Progression ; Ethnic Groups ; Female ; Humans ; Male ; Middle Aged ; Nebulizers and Vaporizers/standards ; New Zealand/epidemiology ; Outcome Assessment, Health Care ; Terbutaline/administration & dosage ; Terbutaline/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study.
Autorzy :
O'Byrne PM; Firestone Institute for Respiratory Health, St Joseph's Healthcare and Department of Medicine, Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada. Electronic address: .
FitzGerald JM; Centre for Lung Health, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada.
Bateman ED; Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Barnes PJ; Airway Disease Section, National Heart and Lung Institute, Imperial College London, London, UK.
Zheng J; State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Gustafson P; AstraZeneca, Gothenburg, Sweden.
Lamarca R; AstraZeneca, Barcelona, Spain.
Puu M; AstraZeneca, Gothenburg, Sweden.
Keen C; AstraZeneca, Gothenburg, Sweden.
Alagappan VKT; AstraZeneca, Gaithersburg, MD, USA.
Reddel HK; Woolcock Institute of Medical Research, University of Sydney, Sydney, NSW, Australia.
Pokaż więcej
Źródło :
The Lancet. Respiratory medicine [Lancet Respir Med] 2021 Feb; Vol. 9 (2), pp. 149-158. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Asthma/*drug therapy
Bronchodilator Agents/*therapeutic use
Budesonide/*therapeutic use
Formoterol Fumarate/*therapeutic use
Adult ; Budesonide/administration & dosage ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Administration Schedule ; Drug Combinations ; Female ; Formoterol Fumarate/administration & dosage ; Humans ; Male ; Severity of Illness Index ; Treatment Outcome
Czasopismo naukowe
Tytuł :
A Pharmacokinetic Bridging Study to Compare Systemic Exposure to Budesonide between Budesonide Oral Suspension and ENTOCORT EC in Healthy Individuals.
Autorzy :
Song IH; Shire Human Genetic Therapies, Inc., a Member of the Takeda Group of Companies, 300 Shire Way, Lexington, MA, 02421, USA. .
Finkelman RD; Shire Human Genetic Therapies, Inc., a Member of the Takeda Group of Companies, 300 Shire Way, Lexington, MA, 02421, USA.
Lan L; Shire Human Genetic Therapies, Inc., a Member of the Takeda Group of Companies, 300 Shire Way, Lexington, MA, 02421, USA.
Pokaż więcej
Źródło :
Drugs in R&D [Drugs R D] 2020 Dec; Vol. 20 (4), pp. 359-367. Date of Electronic Publication: 2020 Oct 15.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
MeSH Terms :
Anti-Inflammatory Agents/*administration & dosage
Anti-Inflammatory Agents/*pharmacokinetics
Budesonide/*administration & dosage
Budesonide/*pharmacokinetics
Eosinophilic Esophagitis/*drug therapy
Administration, Oral ; Adolescent ; Adult ; Anti-Inflammatory Agents/adverse effects ; Biological Availability ; Budesonide/adverse effects ; Clinical Trials, Phase III as Topic ; Cross-Over Studies ; Female ; Humans ; Male ; Middle Aged ; Suspensions ; Tablets, Enteric-Coated ; Young Adult
Czasopismo naukowe
Tytuł :
A mechanistic framework for a priori pharmacokinetic predictions of orally inhaled drugs.
Autorzy :
Hartung N; Institute of Mathematics, University of Potsdam, Potsdam, Germany.
Borghardt JM; Drug Discovery Sciences, Research DMPK, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Pokaż więcej
Źródło :
PLoS computational biology [PLoS Comput Biol] 2020 Dec 15; Vol. 16 (12), pp. e1008466. Date of Electronic Publication: 2020 Dec 15 (Print Publication: 2020).
Typ publikacji :
Journal Article
MeSH Terms :
Models, Biological*
Anti-Asthmatic Agents/*pharmacokinetics
Budesonide/*pharmacokinetics
Fluticasone/*pharmacokinetics
Administration, Inhalation ; Anti-Asthmatic Agents/administration & dosage ; Budesonide/administration & dosage ; Case-Control Studies ; Drug Liberation ; Fluticasone/administration & dosage ; Humans ; Lung/metabolism ; Mucociliary Clearance
Czasopismo naukowe
Tytuł :
[Therapy of radiation-induced esophagits by oro-dispersible budesonide].
Autorzy :
Reinshagen M; Medizinische Klinik I, Klinikum Braunschweig, Germany.
Hoffmann W; Klinik für Radioonkologie und Strahlentherapie, Städtisches Klinikum Braunschweig gGmbH, Standort Celler Straße, Braunschweig, Germany.
Pokaż więcej
Transliterated Title :
Therapie einer akuten Strahlenösophagitis mit orodispersiblem Budesonid.
Źródło :
Zeitschrift fur Gastroenterologie [Z Gastroenterol] 2020 Nov; Vol. 58 (11), pp. 1091-1093. Date of Electronic Publication: 2020 Sep 16.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Anti-Inflammatory Agents/*therapeutic use
Budesonide/*therapeutic use
Esophagitis/*drug therapy
Glucocorticoids/*therapeutic use
Radiation Injuries/*drug therapy
Administration, Oral ; Anti-Inflammatory Agents/administration & dosage ; Budesonide/administration & dosage ; Humans ; Remission Induction ; Treatment Outcome
Czasopismo naukowe
Tytuł :
One More Time: The Impact of Inhaled Corticosteroid Withdrawal on IMPACT.
Autorzy :
Han MK; Division of Pulmonary and Critical Care, University of Michigan, Ann Arbor, Michigan.
Lipson DA; Clinical Sciences, GlaxoSmithKline, Collegeville, Pennsylvania.; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Singh D; The University of Manchester, Manchester University NHS Foundation Trust, Manchester, United Kingdom and.
Martinez FJ; New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York.
Pokaż więcej
Źródło :
American journal of respiratory and critical care medicine [Am J Respir Crit Care Med] 2020 Nov 01; Vol. 202 (9), pp. 1205-1206.
Typ publikacji :
Editorial; Research Support, Non-U.S. Gov't; Comment
MeSH Terms :
Adrenal Cortex Hormones*/adverse effects
Budesonide*
Double-Blind Method
Raport
Tytuł :
Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids.
Autorzy :
Huang TM; Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
Kuo KC; Division of Pulmonary, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan.
Wang YH; Medical Research Center, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
Wang CY; Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
Lai CC; Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, Taiwan. .
Wang HC; Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan. .
Chen L; Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Miaoli County, Taiwan.
Yu CJ; Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.
Pokaż więcej
Corporate Authors :
On the behalf of Taiwan Clinical Trial Consortium for Respiratory Diseases (TCORE)
Źródło :
BMC infectious diseases [BMC Infect Dis] 2020 Sep 25; Vol. 20 (1), pp. 706. Date of Electronic Publication: 2020 Sep 25.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Mycobacterium tuberculosis*
Adrenal Cortex Hormones/*therapeutic use
Adrenergic beta-2 Receptor Agonists/*therapeutic use
Budesonide, Formoterol Fumarate Drug Combination/*therapeutic use
Fluticasone-Salmeterol Drug Combination/*therapeutic use
Pulmonary Disease, Chronic Obstructive/*drug therapy
Tuberculosis/*epidemiology
Administration, Inhalation ; Adrenal Cortex Hormones/administration & dosage ; Adrenal Cortex Hormones/adverse effects ; Adrenergic beta-2 Receptor Agonists/administration & dosage ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Aged ; Budesonide, Formoterol Fumarate Drug Combination/administration & dosage ; Budesonide, Formoterol Fumarate Drug Combination/adverse effects ; Female ; Fluticasone-Salmeterol Drug Combination/administration & dosage ; Fluticasone-Salmeterol Drug Combination/adverse effects ; Follow-Up Studies ; Humans ; Incidence ; Male ; Middle Aged ; Propensity Score ; Risk Factors ; Taiwan/epidemiology
Czasopismo naukowe
Tytuł :
Eosinophilic Gastroenteritis-associated Duodenal Ulcer Successfully Treated with Crushed Budesonide.
Autorzy :
Kubo K; Departments of Gastroenterology, National Hospital Organization Hakodate National Hospital, Japan.
Kimura N; Departments of Pathology, National Hospital Organization Hakodate National Hospital, Japan.
Mabe K; Departments of Gastroenterology, National Hospital Organization Hakodate National Hospital, Japan.
Matsuda S; Departments of Gastroenterology, National Hospital Organization Hakodate National Hospital, Japan.
Tsuda M; Departments of Gastroenterology, National Hospital Organization Hakodate National Hospital, Japan.
Kato M; Departments of Gastroenterology, National Hospital Organization Hakodate National Hospital, Japan.
Pokaż więcej
Źródło :
Internal medicine (Tokyo, Japan) [Intern Med] 2020 Sep 15; Vol. 59 (18), pp. 2249-2254. Date of Electronic Publication: 2020 Jun 15.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Anti-Inflammatory Agents/*therapeutic use
Budesonide/*therapeutic use
Duodenal Ulcer/*drug therapy
Duodenal Ulcer/*etiology
Enteritis/*complications
Eosinophilia/*complications
Gastritis/*complications
Adolescent ; Anti-Inflammatory Agents/administration & dosage ; Biopsy ; Budesonide/administration & dosage ; Duodenal Ulcer/pathology ; Duodenum/pathology ; Endoscopy, Digestive System ; Enteritis/pathology ; Eosinophilia/pathology ; Eosinophils/pathology ; Gastritis/pathology ; Humans ; Male
SCR Disease Name :
Eosinophilic enteropathy
Czasopismo naukowe
Tytuł :
Remarkable Improvement in Clinical Course and Serum KL-6 Levels after Initiation of High-Dose Inhaled Budesonide in Pulmonary Sarcoidosis.
Autorzy :
Morimatsu Y; Division of Respirology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine.; Department of Environmental Medicine, Kurume University School of Medicine.
Okamoto M; Division of Respirology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine.
Kawayama T; Division of Respirology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine.
Mizoguchi Y; Division of Respirology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine.
Imaoka H; Division of Respirology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine.
Ogino H; Shun-yokai Kawazu Internal and Respiratoly Clinic.
Kawazu T; Shun-yokai Kawazu Internal and Respiratoly Clinic.
Ishitake T; Department of Environmental Medicine, Kurume University School of Medicine.
Hoshino T; Division of Respirology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine.
Pokaż więcej
Źródło :
The Kurume medical journal [Kurume Med J] 2020 Jul 01; Vol. 66 (1), pp. 71-75. Date of Electronic Publication: 2020 May 01.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Budesonide*/therapeutic use
Glucocorticoids*/administration & dosage
Sarcoidosis, Pulmonary*/blood
Sarcoidosis, Pulmonary*/drug therapy
Humans ; Mucin-1/blood ; Peptidyl-Dipeptidase A/blood
Czasopismo naukowe
Tytuł :
A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler .
Autorzy :
Syk J; Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.; Academic Primary Health Care Centre, Stockholm, Sweden.; Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Vinge I; Asthma-Allergy-Lung Department, Lidingö Hospital, Lidingö, Sweden.
Sörberg M; Orion Pharma, Sollentuna, Sweden.
Vahteristo M; Orion Corporation, Orion Pharma, Kuopio, Finland.
Rytilä P; Orion Corporation, Orion Pharma, Espoo, Finland. .
Pokaż więcej
Źródło :
Advances in therapy [Adv Ther] 2019 Jul; Vol. 36 (7), pp. 1756-1769. Date of Electronic Publication: 2019 Apr 02.
Typ publikacji :
Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Patient Preference*
Asthma/*drug therapy
Bronchodilator Agents/*therapeutic use
Budesonide/*therapeutic use
Formoterol Fumarate/*therapeutic use
Administration, Inhalation ; Adult ; Budesonide, Formoterol Fumarate Drug Combination/therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; Surveys and Questionnaires ; Therapeutic Equivalency ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Blood eosinophils do not predict inhaled budesonide response in bronchiectasis.
Autorzy :
Aliberti S; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Respiratory Unit and Cystic Fibrosis Adult Center, Milan, Italy .; Università degli Studi di Milano, Dept of Pathophysiology and Transplantation, Milan, Italy.
Sotgiu G; Clinical Epidemiology and Medical Statistics Unit, Dept of Biomedical Sciences, University of Sassari - Research, Medical Education and Professional Development Unit, AOU Sassari, Sassari, Italy.
Martinez Garcia MA; Pneumology Dept, Polytechnic and University La Fe Hospital, Valencia, Spain.; CIBERes de enfermedades respiratorias, Madrid, Spain.
Pokaż więcej
Źródło :
The European respiratory journal [Eur Respir J] 2020 Sep 03; Vol. 56 (3). Date of Electronic Publication: 2020 Sep 03 (Print Publication: 2020).
Typ publikacji :
Letter; Comment
MeSH Terms :
Bronchiectasis*/drug therapy
Budesonide*/therapeutic use
Bronchodilator Agents/therapeutic use ; Eosinophils ; Fluticasone/therapeutic use ; Humans
Opinia redakcyjna
Tytuł :
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
Autorzy :
Rabe KF; From LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, German Center for Lung Research (DZL), Grosshansdorf, Germany (K.F.R.); the Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York (F.J.M.); the Pulmonary Research Institute of Southeast Michigan, Farmington Hills (G.T.F.); the National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing (C.W.); the Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester (D.S.), and the National Heart and Lung Institute, Imperial College London, London (J.A.W.) - both in the United Kingdom; AstraZeneca, Durham, NC (R.T., P. Dorinsky); AstraZeneca, Morristown, NJ (E.S.R., S.B., P. Darken, C.R.); AstraZeneca, Gaithersburg, MD (J.M.); and AstraZeneca, Gothenburg, Sweden (M.A.).
Martinez FJ; From LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, German Center for Lung Research (DZL), Grosshansdorf, Germany (K.F.R.); the Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York (F.J.M.); the Pulmonary Research Institute of Southeast Michigan, Farmington Hills (G.T.F.); the National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing (C.W.); the Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester (D.S.), and the National Heart and Lung Institute, Imperial College London, London (J.A.W.) - both in the United Kingdom; AstraZeneca, Durham, NC (R.T., P. Dorinsky); AstraZeneca, Morristown, NJ (E.S.R., S.B., P. Darken, C.R.); AstraZeneca, Gaithersburg, MD (J.M.); and AstraZeneca, Gothenburg, Sweden (M.A.).
Ferguson GT; From LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, German Center for Lung Research (DZL), Grosshansdorf, Germany (K.F.R.); the Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York (F.J.M.); the Pulmonary Research Institute of Southeast Michigan, Farmington Hills (G.T.F.); the National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing (C.W.); the Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester (D.S.), and the National Heart and Lung Institute, Imperial College London, London (J.A.W.) - both in the United Kingdom; AstraZeneca, Durham, NC (R.T., P. Dorinsky); AstraZeneca, Morristown, NJ (E.S.R., S.B., P. Darken, C.R.); AstraZeneca, Gaithersburg, MD (J.M.); and AstraZeneca, Gothenburg, Sweden (M.A.).
Wang C; From LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, German Center for Lung Research (DZL), Grosshansdorf, Germany (K.F.R.); the Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York (F.J.M.); the Pulmonary Research Institute of Southeast Michigan, Farmington Hills (G.T.F.); the National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing (C.W.); the Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester (D.S.), and the National Heart and Lung Institute, Imperial College London, London (J.A.W.) - both in the United Kingdom; AstraZeneca, Durham, NC (R.T., P. Dorinsky); AstraZeneca, Morristown, NJ (E.S.R., S.B., P. Darken, C.R.); AstraZeneca, Gaithersburg, MD (J.M.); and AstraZeneca, Gothenburg, Sweden (M.A.).
Singh D; From LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, German Center for Lung Research (DZL), Grosshansdorf, Germany (K.F.R.); the Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York (F.J.M.); the Pulmonary Research Institute of Southeast Michigan, Farmington Hills (G.T.F.); the National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing (C.W.); the Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester (D.S.), and the National Heart and Lung Institute, Imperial College London, London (J.A.W.) - both in the United Kingdom; AstraZeneca, Durham, NC (R.T., P. Dorinsky); AstraZeneca, Morristown, NJ (E.S.R., S.B., P. Darken, C.R.); AstraZeneca, Gaithersburg, MD (J.M.); and AstraZeneca, Gothenburg, Sweden (M.A.).
Wedzicha JA; From LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, German Center for Lung Research (DZL), Grosshansdorf, Germany (K.F.R.); the Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York (F.J.M.); the Pulmonary Research Institute of Southeast Michigan, Farmington Hills (G.T.F.); the National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing (C.W.); the Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester (D.S.), and the National Heart and Lung Institute, Imperial College London, London (J.A.W.) - both in the United Kingdom; AstraZeneca, Durham, NC (R.T., P. Dorinsky); AstraZeneca, Morristown, NJ (E.S.R., S.B., P. Darken, C.R.); AstraZeneca, Gaithersburg, MD (J.M.); and AstraZeneca, Gothenburg, Sweden (M.A.).
Trivedi R; From LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, German Center for Lung Research (DZL), Grosshansdorf, Germany (K.F.R.); the Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York (F.J.M.); the Pulmonary Research Institute of Southeast Michigan, Farmington Hills (G.T.F.); the National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing (C.W.); the Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester (D.S.), and the National Heart and Lung Institute, Imperial College London, London (J.A.W.) - both in the United Kingdom; AstraZeneca, Durham, NC (R.T., P. Dorinsky); AstraZeneca, Morristown, NJ (E.S.R., S.B., P. Darken, C.R.); AstraZeneca, Gaithersburg, MD (J.M.); and AstraZeneca, Gothenburg, Sweden (M.A.).
St Rose E; From LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, German Center for Lung Research (DZL), Grosshansdorf, Germany (K.F.R.); the Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York (F.J.M.); the Pulmonary Research Institute of Southeast Michigan, Farmington Hills (G.T.F.); the National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing (C.W.); the Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester (D.S.), and the National Heart and Lung Institute, Imperial College London, London (J.A.W.) - both in the United Kingdom; AstraZeneca, Durham, NC (R.T., P. Dorinsky); AstraZeneca, Morristown, NJ (E.S.R., S.B., P. Darken, C.R.); AstraZeneca, Gaithersburg, MD (J.M.); and AstraZeneca, Gothenburg, Sweden (M.A.).
Ballal S; From LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, German Center for Lung Research (DZL), Grosshansdorf, Germany (K.F.R.); the Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York (F.J.M.); the Pulmonary Research Institute of Southeast Michigan, Farmington Hills (G.T.F.); the National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing (C.W.); the Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester (D.S.), and the National Heart and Lung Institute, Imperial College London, London (J.A.W.) - both in the United Kingdom; AstraZeneca, Durham, NC (R.T., P. Dorinsky); AstraZeneca, Morristown, NJ (E.S.R., S.B., P. Darken, C.R.); AstraZeneca, Gaithersburg, MD (J.M.); and AstraZeneca, Gothenburg, Sweden (M.A.).
McLaren J; From LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, German Center for Lung Research (DZL), Grosshansdorf, Germany (K.F.R.); the Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York (F.J.M.); the Pulmonary Research Institute of Southeast Michigan, Farmington Hills (G.T.F.); the National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing (C.W.); the Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester (D.S.), and the National Heart and Lung Institute, Imperial College London, London (J.A.W.) - both in the United Kingdom; AstraZeneca, Durham, NC (R.T., P. Dorinsky); AstraZeneca, Morristown, NJ (E.S.R., S.B., P. Darken, C.R.); AstraZeneca, Gaithersburg, MD (J.M.); and AstraZeneca, Gothenburg, Sweden (M.A.).
Darken P; From LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, German Center for Lung Research (DZL), Grosshansdorf, Germany (K.F.R.); the Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York (F.J.M.); the Pulmonary Research Institute of Southeast Michigan, Farmington Hills (G.T.F.); the National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing (C.W.); the Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester (D.S.), and the National Heart and Lung Institute, Imperial College London, London (J.A.W.) - both in the United Kingdom; AstraZeneca, Durham, NC (R.T., P. Dorinsky); AstraZeneca, Morristown, NJ (E.S.R., S.B., P. Darken, C.R.); AstraZeneca, Gaithersburg, MD (J.M.); and AstraZeneca, Gothenburg, Sweden (M.A.).
Aurivillius M; From LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, German Center for Lung Research (DZL), Grosshansdorf, Germany (K.F.R.); the Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York (F.J.M.); the Pulmonary Research Institute of Southeast Michigan, Farmington Hills (G.T.F.); the National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing (C.W.); the Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester (D.S.), and the National Heart and Lung Institute, Imperial College London, London (J.A.W.) - both in the United Kingdom; AstraZeneca, Durham, NC (R.T., P. Dorinsky); AstraZeneca, Morristown, NJ (E.S.R., S.B., P. Darken, C.R.); AstraZeneca, Gaithersburg, MD (J.M.); and AstraZeneca, Gothenburg, Sweden (M.A.).
Reisner C; From LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, German Center for Lung Research (DZL), Grosshansdorf, Germany (K.F.R.); the Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York (F.J.M.); the Pulmonary Research Institute of Southeast Michigan, Farmington Hills (G.T.F.); the National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing (C.W.); the Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester (D.S.), and the National Heart and Lung Institute, Imperial College London, London (J.A.W.) - both in the United Kingdom; AstraZeneca, Durham, NC (R.T., P. Dorinsky); AstraZeneca, Morristown, NJ (E.S.R., S.B., P. Darken, C.R.); AstraZeneca, Gaithersburg, MD (J.M.); and AstraZeneca, Gothenburg, Sweden (M.A.).
Dorinsky P; From LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, German Center for Lung Research (DZL), Grosshansdorf, Germany (K.F.R.); the Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York (F.J.M.); the Pulmonary Research Institute of Southeast Michigan, Farmington Hills (G.T.F.); the National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing (C.W.); the Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester (D.S.), and the National Heart and Lung Institute, Imperial College London, London (J.A.W.) - both in the United Kingdom; AstraZeneca, Durham, NC (R.T., P. Dorinsky); AstraZeneca, Morristown, NJ (E.S.R., S.B., P. Darken, C.R.); AstraZeneca, Gaithersburg, MD (J.M.); and AstraZeneca, Gothenburg, Sweden (M.A.).
Pokaż więcej
Corporate Authors :
ETHOS Investigators
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Jul 02; Vol. 383 (1), pp. 35-48. Date of Electronic Publication: 2020 Jun 24.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Adrenergic beta-2 Receptor Agonists/*administration & dosage
Budesonide/*administration & dosage
Formoterol Fumarate/*administration & dosage
Glucocorticoids/*administration & dosage
Glycopyrrolate/*administration & dosage
Muscarinic Antagonists/*administration & dosage
Pulmonary Disease, Chronic Obstructive/*drug therapy
Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Adult ; Aged ; Aged, 80 and over ; Budesonide/adverse effects ; Double-Blind Method ; Drug Combinations ; Female ; Forced Expiratory Volume/drug effects ; Formoterol Fumarate/adverse effects ; Glucocorticoids/adverse effects ; Glycopyrrolate/adverse effects ; Humans ; Intention to Treat Analysis ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Muscarinic Antagonists/adverse effects ; Pulmonary Disease, Chronic Obstructive/mortality
Czasopismo naukowe
Tytuł :
Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial.
Autorzy :
Hardy J; Medical Research Institute of New Zealand, Newtown, Wellington, New Zealand.
Baggott C; Medical Research Institute of New Zealand, Newtown, Wellington, New Zealand.
Fingleton J; Medical Research Institute of New Zealand, Newtown, Wellington, New Zealand; Capital and Coast District Health Board, Wellington, New Zealand.
Reddel HK; Woolcock Institute of Medical Research, University of Sydney, Sydney, NSW, Australia.
Hancox RJ; Waikato Hospital, Hamilton, New Zealand; University of Otago, Dunedin, New Zealand.
Harwood M; University of Auckland, Auckland, New Zealand.
Corin A; Clinical Horizons, Tauranga, New Zealand.
Sparks J; Medical Research Institute of New Zealand, Newtown, Wellington, New Zealand.
Hall D; Medical Research Institute of New Zealand, Newtown, Wellington, New Zealand.
Sabbagh D; Medical Research Institute of New Zealand, Newtown, Wellington, New Zealand.
Mane S; Medical Research Institute of New Zealand, Newtown, Wellington, New Zealand.
Vohlidkova A; Medical Research Institute of New Zealand, Newtown, Wellington, New Zealand.
Martindale J; Medical Research Institute of New Zealand, Newtown, Wellington, New Zealand.
Williams M; Medical Research Institute of New Zealand, Newtown, Wellington, New Zealand.
Shirtcliffe P; Medical Research Institute of New Zealand, Newtown, Wellington, New Zealand.
Holliday M; Medical Research Institute of New Zealand, Newtown, Wellington, New Zealand.
Weatherall M; University of Otago Wellington, Wellington, New Zealand.
Beasley R; Medical Research Institute of New Zealand, Newtown, Wellington, New Zealand; Capital and Coast District Health Board, Wellington, New Zealand. Electronic address: .
Pokaż więcej
Corporate Authors :
PRACTICAL study team
Źródło :
Lancet (London, England) [Lancet] 2019 Sep 14; Vol. 394 (10202), pp. 919-928. Date of Electronic Publication: 2019 Aug 23.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-Asthmatic Agents/*therapeutic use
Asthma/*drug therapy
Budesonide, Formoterol Fumarate Drug Combination/*therapeutic use
Adolescent ; Adult ; Aged ; Anti-Asthmatic Agents/administration & dosage ; Bronchodilator Agents/administration & dosage ; Bronchodilator Agents/therapeutic use ; Budesonide/administration & dosage ; Budesonide/therapeutic use ; Budesonide, Formoterol Fumarate Drug Combination/administration & dosage ; Drug Administration Schedule ; Equivalence Trials as Topic ; Female ; Glucocorticoids/administration & dosage ; Glucocorticoids/therapeutic use ; Humans ; Male ; Middle Aged ; Nebulizers and Vaporizers ; Severity of Illness Index ; Terbutaline/administration & dosage ; Terbutaline/therapeutic use ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Budesonide use and misuse in sports: Elimination profiles of budesonide and metabolites after intranasal, high-dose inhaled and oral administrations.
Autorzy :
Coll S; IMIM (Hospital del Mar Medical Research Institute), Doping Control Research Group, Catalonian Antidoping Laboratory, Barcelona, Spain.; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
Monfort N; IMIM (Hospital del Mar Medical Research Institute), Doping Control Research Group, Catalonian Antidoping Laboratory, Barcelona, Spain.
Matabosch X; IMIM (Hospital del Mar Medical Research Institute), Doping Control Research Group, Catalonian Antidoping Laboratory, Barcelona, Spain.
Papakonstantinou K; IMIM (Hospital del Mar Medical Research Institute), Doping Control Research Group, Catalonian Antidoping Laboratory, Barcelona, Spain.
Pérez-Mañá C; Department of Clinical Pharmacology, Hospital Universitari Germans Trias i Pujol (HUGTP-IGTP), Badalona, Spain.; Department of Pharmacology, Therapeutics and Toxicology, Autonomous University of Barcelona, Cerdanyola del Vallès, Spain.
Mateus JA; IMIM (Hospital del Mar Medical Research Institute), Human Pharmacology and Clinical Neurosciences Research Group, Barcelona, Spain.
Ventura R; IMIM (Hospital del Mar Medical Research Institute), Doping Control Research Group, Catalonian Antidoping Laboratory, Barcelona, Spain.; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
Pokaż więcej
Źródło :
Drug testing and analysis [Drug Test Anal] 2020 May; Vol. 12 (5), pp. 629-636. Date of Electronic Publication: 2019 Aug 09.
Typ publikacji :
Journal Article
MeSH Terms :
Budesonide/*pharmacokinetics
Doping in Sports/*prevention & control
Substance Abuse Detection/*methods
Administration, Inhalation ; Administration, Intranasal ; Administration, Oral ; Adult ; Budesonide/administration & dosage ; Budesonide/analogs & derivatives ; Budesonide/urine ; Chromatography, Liquid ; Female ; Glucocorticoids/administration & dosage ; Glucocorticoids/pharmacokinetics ; Glucocorticoids/urine ; Humans ; Male ; Sex Factors ; Tandem Mass Spectrometry ; Young Adult
Czasopismo naukowe
Tytuł :
Budesonide versus systemic corticosteroids in IgA Nephropathy: A retrospective, propensity-matched comparison.
Autorzy :
Ismail G; Department of Nephrology, Fundeni Clinical Institute.; Department of Uronephrology, 'Carol Davila' University of Medicine and Pharmacy.
Obrişcă B; Department of Nephrology, Fundeni Clinical Institute.; Department of Uronephrology, 'Carol Davila' University of Medicine and Pharmacy.
Jurubiţă R; Department of Nephrology, Fundeni Clinical Institute.; Department of Uronephrology, 'Carol Davila' University of Medicine and Pharmacy.
Andronesi A; Department of Nephrology, Fundeni Clinical Institute.; Department of Uronephrology, 'Carol Davila' University of Medicine and Pharmacy.
Sorohan B; Department of Nephrology, Fundeni Clinical Institute.; Department of Uronephrology, 'Carol Davila' University of Medicine and Pharmacy.
Vornicu A; Department of Nephrology, Fundeni Clinical Institute.
Sinescu I; Department of Uronephrology, 'Carol Davila' University of Medicine and Pharmacy.; Center of Uronephrology and Renal Transplantation, Fundeni Clinical Institute, Bucharest, Romania.
Hârza M; Department of Uronephrology, 'Carol Davila' University of Medicine and Pharmacy.; Center of Uronephrology and Renal Transplantation, Fundeni Clinical Institute, Bucharest, Romania.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Jun 26; Vol. 99 (26), pp. e21000.
Typ publikacji :
Journal Article
MeSH Terms :
Adrenal Cortex Hormones/*standards
Budesonide/*standards
Glomerulonephritis, IGA/*drug therapy
Adrenal Cortex Hormones/adverse effects ; Adrenal Cortex Hormones/therapeutic use ; Adult ; Budesonide/adverse effects ; Budesonide/therapeutic use ; Female ; Glomerular Filtration Rate/drug effects ; Hematuria/drug therapy ; Hematuria/prevention & control ; Humans ; Male ; Middle Aged ; Propensity Score ; Proteinuria/drug therapy ; Proteinuria/prevention & control ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Nasal nebulization inhalation of budesonide for chronic rhinosinusitis with nasal polyps: A protocol for systematic review and meta-analysis.
Autorzy :
Zheng PJ; Department of Otolaryngology, First Affiliated Hospital of Jiamusi University.
Zhang YY; Department of Otolaryngology, Jiamusi University Affiliated Stomatological Hospital.
Zhang SH; Department of Otolaryngology, First Affiliated Hospital of Jiamusi University.
Liu GF; Department of Otolaryngology, First Affiliated Hospital of Jiamusi University.
Wang JS; Department of Otorhinolaryngology, Second Hospital of Jiamusi Agricultural Reclamation, Jiamusi, China.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 May 29; Vol. 99 (22), pp. e20354.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Anti-Inflammatory Agents/*therapeutic use
Budesonide/*therapeutic use
Nasal Polyps/*drug therapy
Rhinitis/*drug therapy
Sinusitis/*drug therapy
Administration, Intranasal ; Anti-Inflammatory Agents/administration & dosage ; Budesonide/administration & dosage ; Chronic Disease ; Humans ; Nebulizers and Vaporizers
Czasopismo naukowe
Tytuł :
Treatment strategies for protein-losing enteropathy in Fontan-palliated patients.
Autorzy :
Schleiger A; Department of Congenital Heart Disease/Pediatric Cardiology, Berlin, German Heart Center Berlin, Augustenburger Platz 1, 13353Berlin, Germany.
Ovroutski S; Department of Congenital Heart Disease/Pediatric Cardiology, Berlin, German Heart Center Berlin, Augustenburger Platz 1, 13353Berlin, Germany.
Peters B; Department of Congenital Heart Disease/Pediatric Cardiology, Berlin, German Heart Center Berlin, Augustenburger Platz 1, 13353Berlin, Germany.
Schubert S; Department of Congenital Heart Disease/Pediatric Cardiology, Berlin, German Heart Center Berlin, Augustenburger Platz 1, 13353Berlin, Germany.
Photiadis J; Department of Congenital Heart Surgery, German Heart Center Berlin, Augustenburger Platz 1, 13353Berlin, Germany.
Berger F; Department of Congenital Heart Disease/Pediatric Cardiology, Berlin, German Heart Center Berlin, Augustenburger Platz 1, 13353Berlin, Germany.; Department of Pediatric Cardiology, Charité - Universitaetsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353Berlin, Germany.; Partner Site Berlin, DZHK (German Center for Cardiovascular Research), Oudenarder Straße 16, 13347Berlin, Germany.
Kramer P; Department of Congenital Heart Disease/Pediatric Cardiology, Berlin, German Heart Center Berlin, Augustenburger Platz 1, 13353Berlin, Germany.
Pokaż więcej
Źródło :
Cardiology in the young [Cardiol Young] 2020 May; Vol. 30 (5), pp. 698-709. Date of Electronic Publication: 2020 May 04.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Anti-Inflammatory Agents/*therapeutic use
Budesonide/*therapeutic use
Fontan Procedure/*adverse effects
Protein-Losing Enteropathies/*therapy
Vasodilator Agents/*therapeutic use
Adolescent ; Adult ; Anti-Inflammatory Agents/adverse effects ; Budesonide/adverse effects ; Child ; Combined Modality Therapy ; Disease Management ; Female ; Heart Transplantation ; Hemodynamics ; Humans ; Male ; Protein-Losing Enteropathies/etiology ; Protein-Losing Enteropathies/physiopathology ; Remission Induction ; Retrospective Studies ; Risk Factors ; Survival Analysis ; Young Adult
Czasopismo naukowe
Tytuł :
Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults.
Autorzy :
Dorinsky P; AstraZeneca, Durham, NC, USA. Electronic address: .
DePetrillo P; Pharmaron, Baltimore, MD, USA.
DeAngelis K; AstraZeneca, Durham, NC, USA.
Trivedi R; AstraZeneca, Durham, NC, USA.
Darken P; AstraZeneca, Morristown, NJ, USA.
Gillen M; AstraZeneca, Gaithersburg, MD, USA.
Pokaż więcej
Źródło :
Clinical therapeutics [Clin Ther] 2020 Apr; Vol. 42 (4), pp. 634-648. Date of Electronic Publication: 2020 Apr 03.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Metered Dose Inhalers*
Anti-Asthmatic Agents/*pharmacokinetics
Bronchodilator Agents/*pharmacokinetics
Budesonide/*pharmacokinetics
Formoterol Fumarate/*pharmacokinetics
Glycopyrrolate/*pharmacokinetics
Muscarinic Antagonists/*pharmacokinetics
Adult ; Anti-Asthmatic Agents/administration & dosage ; Biological Availability ; Bronchodilator Agents/administration & dosage ; Budesonide/administration & dosage ; Cross-Over Studies ; Drug Combinations ; Female ; Formoterol Fumarate/administration & dosage ; Glycopyrrolate/administration & dosage ; Healthy Volunteers ; Humans ; Male ; Muscarinic Antagonists/administration & dosage ; Young Adult
Czasopismo naukowe
Tytuł :
Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort (budesonide/formoterol) pressurized metered dose inhaler.
Autorzy :
Gillen M; AstraZeneca - Quantitative Clinical Pharmacology, Gaithersburg, USA. Electronic address: .
Forte P; PAREXEL International Limited, PAREXEL Early Phase Clinical Unit, Level 7, Northwick Park Hospital, Watford Road, Harrow, Middlesex, HA1 3UJ, UK. Electronic address: .
Svensson JO; AstraZeneca, Pepparedsleden 1, 431 50, Mölndal, Gothenburg, Sweden; Chalmers University of Technology, SE-412 96, Gothenburg, Sweden. Electronic address: .
Lamarca R; AstraZeneca, Avenida Diagonal, 615, 08028, Barcelona, Catalonia, Spain. Electronic address: .
Burke J; JB Stats Ltd, Reading, UK; AstraZeneca, Academy House, 136 Hills Road, Cambridge, CB2 8PA, UK. Electronic address: .
Rask K; AstraZeneca, Pepparedsleden 1, 431 50, Mölndal, Gothenburg, Sweden. Electronic address: .
Larsdotter Nilsson U; AstraZeneca, Pepparedsleden 1, 431 50, Mölndal, Gothenburg, Sweden. Electronic address: .
Eckerwall G; AstraZeneca, Pepparedsleden 1, 431 50, Mölndal, Gothenburg, Sweden. Electronic address: .
Pokaż więcej
Źródło :
Pulmonary pharmacology & therapeutics [Pulm Pharmacol Ther] 2018 Oct; Vol. 52, pp. 7-17. Date of Electronic Publication: 2018 Aug 02.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Inhalation Spacers*
Budesonide, Formoterol Fumarate Drug Combination/*administration & dosage
Budesonide, Formoterol Fumarate Drug Combination/*pharmacokinetics
Lung/*metabolism
Administration, Inhalation ; Adult ; Biological Availability ; Bronchodilator Agents/administration & dosage ; Budesonide/blood ; Budesonide/pharmacokinetics ; Cross-Over Studies ; Female ; Formoterol Fumarate/blood ; Formoterol Fumarate/pharmacokinetics ; Humans ; Male ; Metered Dose Inhalers ; Middle Aged
Czasopismo naukowe
Tytuł :
Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD.
Autorzy :
Dunn LJ; Clinical Research of West Florida, Clearwater, FL, USA. Electronic address: .
Kerwin EM; Clinical Research Institute of Southern Oregon, Medford, OR, USA. Electronic address: .
DeAngelis K; Formerly of AstraZeneca, Durham, NC, USA. Electronic address: .
Darken P; AstraZeneca, Morristown, NJ, USA. Electronic address: .
Gillen M; AstraZeneca, Gaithersburg, MD, USA. Electronic address: .
Dorinsky P; AstraZeneca, Durham, NC, USA. Electronic address: .
Pokaż więcej
Źródło :
Pulmonary pharmacology & therapeutics [Pulm Pharmacol Ther] 2020 Feb; Vol. 60, pp. 101873. Date of Electronic Publication: 2019 Dec 10.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Bronchodilator Agents/*administration & dosage
Budesonide/*pharmacokinetics
Drug Delivery Systems/*methods
Formoterol Fumarate/*pharmacokinetics
Glycopyrrolate/*pharmacokinetics
Pulmonary Disease, Chronic Obstructive/*drug therapy
Administration, Inhalation ; Adult ; Aged ; Aged, 80 and over ; Bronchodilator Agents/blood ; Bronchodilator Agents/pharmacokinetics ; Budesonide/administration & dosage ; Budesonide/blood ; Double-Blind Method ; Drug Combinations ; Female ; Formoterol Fumarate/administration & dosage ; Formoterol Fumarate/blood ; Glycopyrrolate/administration & dosage ; Glycopyrrolate/blood ; Humans ; Male ; Metered Dose Inhalers ; Middle Aged ; Pulmonary Disease, Chronic Obstructive/metabolism ; Random Allocation
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies